FDA Approved: CUROSURF — Supplemental Application (Chiesi USA, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for Curosurf (poractant alfa) submitted by Chiesi USA, Inc., pertaining to the existing product authorization.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neonatal Respiratory Distress Syndrome

Drugs mentioned

• Curosurf (poractant alfa)

Snippet

SUPPL AP for CUROSURF (PORACTANT ALFA)